These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17609622)

  • 1. Hyperimmunoglobulinemia in pediatric-onset type 1 Gaucher disease and effects of enzyme replacement therapy.
    Wine E; Yaniv I; Cohen IJ
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):451-7. PubMed ID: 17609622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin abnormalities and effects of enzyme replacement therapy in children with Gaucher disease.
    Arıkan-Ayyıldız Z; Yuce A; Uslu-Kızılkan N; Demir H; Gurakan F
    Pediatr Blood Cancer; 2011 Apr; 56(4):664-6. PubMed ID: 21298757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperimmunoglobulinemia in pediatric patients with Gaucher disease in Southern Brazil.
    Arıkan-Ayyıldız Z; Yuce A; Uslu-Kızılkan N; Demir H; Gürakan F
    Pediatr Blood Cancer; 2012 Aug; 59(2):340. PubMed ID: 22431267
    [No Abstract]   [Full Text] [Related]  

  • 5. Hyperimmunoglobulinemia in pediatric Gaucher patients in Southern Brazil.
    Vairo F; Alegra T; Dornelles A; Mittelstadt S; Netto CB; Schwartz IV
    Pediatr Blood Cancer; 2012 Aug; 59(2):339. PubMed ID: 22457220
    [No Abstract]   [Full Text] [Related]  

  • 6. Enzyme replacement therapy decreases hypergammaglobulinemia in Gaucher's disease.
    Deibener J; Kaminsky P; Jacob C; Dousset B; Klein M; Duc M
    Haematologica; 1998 May; 83(5):479-80. PubMed ID: 9658738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperimmunoglobulinemia and IgG Subclass Abnormalities in Children With Gaucher Disease.
    Marzouk I; Deghady A; Omar OM; Ashour RS
    J Pediatr Hematol Oncol; 2019 Oct; 41(7):e416-e420. PubMed ID: 31385859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: a case report.
    Martinez-Redondo C; Ortuño FJ; Lozano ML; Jerez A; del Mar Osma M; Giraldo P; Vicente V
    J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S265-7. PubMed ID: 19562501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gaucher's disease: a disease with chronic stimulation of the immune system.
    Shoenfeld Y; Gallant LA; Shaklai M; Livni E; Djaldetti M; Pinkhas J
    Arch Pathol Lab Med; 1982 Aug; 106(8):388-91. PubMed ID: 7049116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
    Kauli R; Zaizov R; Lazar L; Pertzelan A; Laron Z; Galatzer A; Phillip M; Yaniv Y; Cohen IJ
    Isr Med Assoc J; 2000 Feb; 2(2):158-63. PubMed ID: 10804944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease.
    Hollak CE; Evers L; Aerts JM; van Oers MH
    Blood Cells Mol Dis; 1997 Aug; 23(2):201-12. PubMed ID: 9236158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaphylactoid reaction to imiglucerase, but not to alglucerase, in a type I Gaucher patient.
    Aviner S; Levy Y; Yaniv I; Cohen IJ
    Blood Cells Mol Dis; 1999 Apr; 25(2):92-4. PubMed ID: 10389590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-term international safety experience of imiglucerase therapy for Gaucher disease.
    Starzyk K; Richards S; Yee J; Smith SE; Kingma W
    Mol Genet Metab; 2007 Feb; 90(2):157-63. PubMed ID: 17079176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R; Arndt S; Levin JB
    S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [French results of enzyme replacement therapy in Gaucher's disease].
    Schaison G; Caubel I; Belmatoug N; Billette de Villemeur T; Saudubray JM
    Bull Acad Natl Med; 2002; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme therapy in Gaucher disease type 2: an autopsy case.
    Takahashi T; Yoshida Y; Sato W; Yano T; Shoji Y; Sawaishi Y; Sakuma I; Sashi T; Enomoto K; Ida H; Takada G
    Tohoku J Exp Med; 1998 Oct; 186(2):143-9. PubMed ID: 10223617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration.
    Rosenberg M; Kingma W; Fitzpatrick MA; Richards SM
    Blood; 1999 Mar; 93(6):2081-8. PubMed ID: 10068682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.